Sofosbuvir tied to rare cases of bradyarrhythmia

Sofosbuvir tied to rare cases of bradyarrhythmia

(HealthDay)—One of the new, highly effective drugs for treating hepatitis C can cause bradyarrhythmia in some patients, according to a research letter published in the Nov. 5 issue of the New England Journal of Medicine.

Doctors at a Paris hospital found that three out of 415 C patients treated with sofosbuvir during 2014 developed bradyarrhythmia.

In all three cases, the were also receiving other hepatitis C medications, including daclatasvir, simeprevir, and ribavirin, according to the report.

"The potential cardiac toxicity of sofosbuvir-containing regimens suggests the need for caution with the use of such regimens," the Parisian doctors concluded in the report. They suggested that doctors review other medications and potential risk factors for an abnormal heart rate before prescribing the drug. And, they pointed out the possible need to monitor when starting treatment with sofosbuvir.

Explore further

Sofosbuvir plus ledipasvir seems effective for HCV genotype 1

More information: Full Text
Journal information: New England Journal of Medicine

Copyright © 2015 HealthDay. All rights reserved.

Citation: Sofosbuvir tied to rare cases of bradyarrhythmia (2015, November 5) retrieved 22 September 2020 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors

User comments